Evaluation of enteral feeding success in head injured patients placed in pentobarbital induced comas

Abstract of Distinction from Clinical Nutrition Week, Las Vegas, NV, February 8-10, 2010

Fruit and vegetable processing and food technology: a summary of research

Evaluation of tomato cultivars for processing / W. A. Gould and R. Stillabower -- Physical and subjective color evaluation of tomato juice / Kenneth L. Beck and W. A. Gould -- Flavor evaluation of tomato juice fortified with sugar and citric acid / J. A. Gould and W. A. Gould -- Effects of citric acid and sugar ratios on thermal resistance of Bacillus coagulans var. thermoacidurans in tomato juice / Dennis L. Gierhart and W. A. Gould -- Protein bodies of the germinating tomato seed cotyledon / L. K. Eggers and J. R. Geisman -- Studies concerning the protein of tomato seeds recovered from tomato cannery waste / L. K. Eggers and J. R. Geisman -- Lipid composition of cucumber / A. C. Peng -- Fatty acids in fresh and recycled brines / A. C. Peng and J. R. Geisman -- Repeated recycling of spent pickle brine affects pickle quality / J. R. Geisman and M. Lazear -- Evaluation of snap bean cultivars for processing / W. Gould, J. Gould, J. Mount, M. Skoog and R. Stillabower -- Evaluating strawberries for freezing / J. F. Gallander and J. F. Stetson -- Grapes for Ohio wines / J. F. Gallander and J. F. Stetso

1976 Research Progress Reports; Fruit and Vegetable Processing and Food Technology

Evaluation of tomato cultivars for processing / W. A. Gould, R. Stillabower and D. Grindell -- Using tomato seeds / J. R. Geisman -- Evaluation of snap bean cultivars for processing / W. A. Gould and R. Stillabower -- Flame sterilization of canned green beans / J. R. Mount and W. A. Gould -- Flame sterilization of canned peas / J. R. Ice, J. R. Mount and W. A. Gould -- Flame sterilization of other canned products / John Mount and W. A. Gould -- Determination of factors affecting heat penetration in flame sterilized canned whole kernel sweet corn / R. Joseph and W. A. Gould -- Geotrichum candidum: the new FDA indicator of plant sanitation for the food processing industry / J. G. Fox and W. A. Gould -- Recycling spent pickling brines ; Uses for the outer green leaves of cabbage / J. R. Geisman -- The development of a fish spread by the utilization of freshwater drum from Lake Erie / J. D. Morgan and W. A. Gould -- Development of a sausage product from Lake Erie freshwater drum / S. Hauck and W. A. Gould -- Utilization of Lake Erie freshwater drum for fish sticks / W. Stone and W. A. Gould -- Acidification and thermal processing of tripolyphosphate treated freshwater drum fillets / T. F. Chin and W. A. Gould -- Effect of lipid and fatty acid composition on keeping quality / Andrew C. Peng -- Grape lipids / P. A. Higgins and A. C. Peng -- The effect of maturation on the lipid content of 'Concord' grapes / John A. Bauman and James F. Gallander -- Stability of ascorbic acid in fortified apple juice / M. I. Mahmoud and W. A. Gould -- Wine deacidification with mixed cultures of Schizosaccharomyces pombe and Saccharomyces cerevisiae ; The effect of bacterial inoculum on malo-lactic fermentation in wines ; Concentrations of tartaric and malic acids of several wine varieties grown in Ohio / J. F. Gallander and J. F. Stetso

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

The relationship between genotype, developmental stability and mating performance: disentangling the epigenetic causes.

Developmental stability (DS) may confer an advantage in competition for mates. The present study tests this hypothesis using Drosophila immigrans, and proposes a novel approach to help broadly define the epigenetic factors causing such an effect. We first estimated the magnitude of isofemale heritability in sternopleural bristle fluctuating asymmetry (FA), using replicate genetic lines extracted from nature. Positional FA (PFA) exhibited significant among-line variation, and the heritability estimate of 0.10 (0.046 s.e.m.) was statistically significant. Among individual males, there was a significant positive relationship between PFA and copulation latency (time elapsed between introduction of females and copulation) and duration, but not copulation frequency. Moreover, high-DS lines exhibited significantly shorter copulation latency and duration compared with low-DS lines. When these components of sexual performance were again contrasted between lines with among-individual differences in bristle asymmetry controlled statistically, significant line effects on copulation latency and duration disappeared. The results suggest that deficits in the developmental apparatus underlying one particular trait can compromise individual sexual performance, and weaken the hypothesis that FA is a cue of overall 'genetic quality'

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure

This article provides a detailed overview of the rationale for key aspects of the protocol of the Digitalis Investigation Group (DIG) trial. It also highlights unusual aspects of the study implementation and the baseline characteristics. The DIG trial is a large, simple, international placebo-controlled trial whose primary objective is to determine the effect of digoxin on all cause mortality in patients with clinical heart failure who are in sinus rhythm and whose ejection fraction is less than or equal to 0.45. An ancillary study examines the effect in those with an ejection fraction > 0.45. Key aspects of the trial include the simplicity of the design, broad eligibility criteria, essential data collection, and inclusion of various types of centers. A total of 302 centers in the United States and Canada enrolled 7788 patients between February 1991 and September 1993. Follow-up continued until December 1995 with the results available in Spring 1996